Localised treatment and 6-month outcomes in patients with cytomegalovirus retinitis at a tertiary ophthalmology service in Ga-Rankuwa by Laher, F et al.











South Africa has both a high burden of HIV disease1 and a 
large, expanding antiretroviral therapy (ART) programme.2 It 
is noteworthy that many South African HIV patients present 
for treatment when the CD4 count is less than 50 cells/μl.3 
Particularly in these individuals with advanced immune 
compromise, opportunistic infections such as cytomegalovirus 
(CMV) may present. The most commonly recognised 
manifestation of CMV is CMV retinitis (CMV-R), but 
pneumonitis, colitis, oesophagitis, adrenalitis, and neurological 
involvement are also described.4
In Africa, data describing the disease burden of CMV-R 
in the ART era are limited. In the pre-ART era, a 20-month 
longitudinal study in AIDS patients in Togo confirmed a 21.4% 
incidence. 5 Also in the pre-ART roll-out era in South Africa, 
90 AIDS patients were treated for CMV-R at the University 
of Natal, and the incidence was noted to increase with time.6 
A cross-sectional study screening all HIV patients with CD4 
counts of <50 cells/μl in Khayelitsha, South Africa, found 2% 
of these patients to have CMV-R.5
CMV-R treatment strategies include localised and systemic 
therapies optimally used in combination and in initiation and 
maintenance phases, and the use of ART in the context of 
HIV diagnosis. CMV has been called the ‘neglected disease 
of the AIDS pandemic’, in part because of limited access to 
treatment, especially in the developing world, where localised 
intra-ocular ganciclovir implants and systemic oral valganciclovir 
are unavailable or too costly.5 Intravitreal ganciclovir injections, 
although more cost-effective, require highly skilled administration 
and may be inconvenient and/or unacceptable to patients.7
ART combined with CMV treatment strategies is associated 
with an improvement in median survival after CMV-R 
diagnosis from 6 months to over 1 year.8,9 There are few ART-
era data for CMV-R from African countries where cost limits 
the use of systemic CMV therapy. 
This study describes the incidence of CMV-R in a public 
hospital outpatient ophthalmology clinic in Ga-Rankuwa, 
South Africa, over a 1-year period and examines treatment 
Objective. There are few data from before the antiretroviral 
therapy (ART) era for cytomegalovirus retinitis (CMV-R) 
from settings where cost limits use of systemic treatment. 
This study examines CMV-R treatment and survival 
outcomes in a public hospital ophthalmology service in Ga-
Rankuwa, South Africa.
Methods. From October 2009 to October 2010, voluntarily 
consenting participants over the age of 15 years with 
incident clinically diagnosed CMV-R seen at the Dr George 
Mukhari Hospital ophthalmology clinic were prospectively 
enrolled in an observational study. Treatment was per clinic 
protocols and patients were followed up with structured data 
collection for up to 6 months. 
Results. Eight individuals, all HIV infected and 50% 
female, were identified and enrolled. At enrolment, median 
age was 38 years (interquartile range (IQR) 32 - 39 years), 
median CD4 count 20 cells/μl (IQR 13 - 46.5 cells/µl), 
and 50% were currently receiving ART (mean duration of 
ART use 18 days, standard deviation (SD) 2.99 days). No 
participant received systemic ganciclovir, but 6 reported 
symptom combinations suggesting systemic CMV: shortness 
of breath (n=3), diarrhoea (n=3) and/or central nervous 
system complaints (n=3). Ten eyes had visual impairment less 
than counting fingers at enrolment. Treatment combinations 
were: ART plus intravitreal ganciclovir (n=5), intravitreal 
ganciclovir alone (n=2), and ART alone (n=1). Six-month 
outcomes were: death (n=1), survival (n=6), loss to follow-up 
(n=3), untraceable (n=1), systemic symptom resolution (4/4), 
visual acuity deterioration (0/5), and persisting uveitis (2/3).
Conclusion. In the ART era, incident CMV-R appears to 
be uncommon in this setting. CMV-R may occur within the 
first 3 weeks after ART initiation. Even in CMV-R patients 
with suggestive systemic symptoms, 6-month survival is 
good despite no systemic CMV therapy.
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A prospective longitudinal observational 
study was conducted at the ophthalmology 
outpatient clinic of the Dr George Mukhari 
Hospital, a state tertiary academic service 
situated in Ga-Rankuwa, Gauteng province, 
South Africa. The hospital has a catchment 
population of 1 800 000 people from the 
surrounding Tshwane and Metsweding areas. 
In 2007, the antenatal HIV seroprevalence in 
Tshwane was 27% and in Metsweding it was 
33%.10 At the time of the study, the hospital 
also offered an on-site HIV clinic with free 
ART access for HIV-infected adults with 
CD4 counts less than 200 cells/µl or World 
Health Organization (WHO) stage 4 disease. 
ARV roll-out began in August 2004. In this 
setting, ophthalmology referrals are made 
by healthcare workers in the hospital and 
HIV clinic or in secondary and primary level 
facilities. Referral is based on presentation 
with any visual symptoms. In 2011, the HIV 
clinic saw 7 853 patients of whom 193 initiated 
ART during that year.
Eligibility
Patients were eligible for entry into the study 
if they were aged 15 years or older; able to 
provide voluntary written informed consent 
(for those 18 years or older) or assent with 
parent/guardian consent (for those between 15 
and 17 years old); and presented at Dr George 
Mukhari Hospital ophthalmology clinic with 
new clinically diagnosed CMV-R during the 
1-year enrolment period of the study.
Case definition
The CMV-R case definition was visualisation 
of at least one of the following on dilated 
pupil indirect ophthalmoscopy: indolent 
retinitis characterised by mild granular retinal 
opacification which may be associated with 
a few punctuate haemorrhages but absent 
vasculitis, or fulminating retinitis characterised 
by mild vitritis, vasculitis with perivascular 
sheathing and retinal opacification, dense, 
white, well-demarcated, geographical area of 
confluent opacification often associated with 
retinal haemorrhages, and slow relentless 
brushfire-like extension along retinal vascular 
arcades that may involve the optic nerve.11
Data collection
From 6 October 2009 to 6 October 2010, 
participants identified by clinic staff as having 
a possible CMV-R diagnosis from routine 
retinal screening (indirect ophthalmoscopy 
with fully dilated pupils) were referred to study 
representatives at the same clinic for assessment 
of eligibility, voluntary informed consent 
procedures and enrolment into the study. 
Structured data collection by 
ophthalmologists was done at enrolment 
on the day of referral, and at months 3 
and 6. This involved two components: (i) a 
clinical interview to record demographics, 
HIV status, CD4 count results, use of ART 
and CMV treatments, ocular symptoms, 
and a brief systemic symptom screen 
probing shortness of breath, diarrhoea, 
fever, headache, change in personality and 
decreased concentration; and (ii) visual 
acuity measurements using a Snellen chart 
or gross visual tests for vision worse than 
6/120, and an ophthalmological examination 
including indirect ophthalmoscopy with fully 
dilated pupils to categorise CMV-R zonal 
location and to assess the presence of CMV-R 
complications, namely vitreous haemorrhage, 
cataract, endophthalmitis and uveitis.
Treatment was neither influenced nor 
provided by the study, but was managed by 
the clinic according to local standard of care. 
Patients were referred to the HIV clinic for ART 
per South African guidelines. Management of 
CMV-R in this setting was predetermined 
by availability of ganciclovir only. Current 
accepted practice in the developing world is 
intravitreal ganciclovir injection twice a week 
for the first 2 weeks, and then weekly until the 
CD4 count recovers to over 150 cells/µl or retinitis 
becomes quiescent. However, intravitreal 
ganciclovir is not recommended for patients 
who will not have recoverable vision, who have 
Table 1. Summary of participant characteristics, treatment and symptoms at baseline and 6 months
Participant
Baseline characteristics

















No Yes Ocular symptoms unresolved but 
systemic symptoms resolved
2 F 31 Ocular dryness Diarrhoea Intravitreal 
ganciclovir
Yes Ocular and systemic symptoms 
resolved
3 M 44 Ocular redness and 
photophobia
Shortness of breath Intravitreal 
ganciclovir
Yes Defaulted follow-up but 
confirmed alive
4 F 39 Decreased vision Nil Intravitreal 
ganciclovir
Yes Death
5 F 31 Ocular dryness Diarrhoea Intravitreal 
ganciclovir
Yes Ocular and systemic symptoms 
resolved






Yes Ocular and systemic symptoms 
resolved
7 M 44 Blind spots, ‘floaters’ Nil Intravitreal 
ganciclovir
No Defaulted follow-up and survival 
not ascertained 
8 M 37 Blind sports, 
photophobia




No Defaulted follow-up but 
confirmed alive











less than 3 clock hours of disease in retinal 
zone 3 and no fundal view, and who cannot 
come for regular injections.6
Telephonic tracing was undertaken for 
participants who did not attend follow-up 
appointments.
Statistical analysis
Descriptive statistics are reported. There were 
insufficient cases reported to analyse risk 
factors for outcomes.
Ethical considerations
Ethical approval was received from the 
Medunsa Research and Ethics Committee 
before initiating the study.
Results
Baseline characteristics
Over the 1-year enrolment period, 8 
individuals were eligible and all agreed to 
participate in the study (Table 1). All were 
HIV infected and 50% were female. The 
median age at first appearance of CMV 
symptoms was 38 years (intraquartile rage 
(IQR) 32 - 39 years). At enrolment, the 
median CD4 count was 20 cells/μl (IQR 
13 - 46.5 cells/μl) and 50% were currently 
receiving ART (mean duration of ART use 
prior to CMV presentation 18 days, standard 
deviation (SD) 3 days).
Presenting ocular symptoms were either 
one or a combination of: blind spots (n=3), 
decreased vision (n=2), dry eyes (n=2), 
photophobia (n=2), eye redness (n=1), visual 
distortions (n=1) and ‘floaters’ (n=1).
Six participants (75%) reported systemic 
symptoms: shortness of breath (n=3), 
diarrhoea (n=3) and/or central nervous 
system complaints of headaches, personality 
changes and/or decreased concentration 
(n=3). 
A summary of visual acuity is presented 
in Table 2. Ten eyes were classified as having 
visual impairment less than counting fingers 
at enrolment. 
Indirect ophthalmoscopy at enrolment 
revealed bilateral retinal involvement in 7 
participants (88%). The most common retinal 
zone affected was zone 3 (10 eyes), then zone 
2 (8 eyes) and zone 1 (6 eyes). Uveitis was 
found in 7 cases, and vitreous haemorrhage 
was present in 1 case (Figs 1 and 2).
Treatment
None of the participants received systemic 
therapy, although 6 complained of systemic 
symptoms. The combination of ART and 
intravitreal ganciclovir injections was given to 
5 participants. Intravitreal ganciclovir alone 
was given to 2 male participants who both 
refused ART and defaulted from study follow-
up. One patient, who had no light perception 
bilaterally, received only ART because visual 
benefit with intravitreal ganciclovir was not 
deemed likely.
Six-month outcomes
By month 6, 1 participant had died, 6 were 
alive and 1 was untraceable. Three participants 
had defaulted from follow-up.
Resolution of symptoms and complications 
at 6 months is described for the 4 participants 
who remained in follow-up. Ocular symptoms 
resolved for all 3 participants who received 
Fig. 2. Fundus photograph of the left eye of the same patient as in Fig. 1. Retinal detachment and retinitis 
are demonstrated by the retinal opacification and frosted branch angiitis, indicating active CMV-R disease.
Fig. 1. Fundus photograph of the right eye of a 40-year-old woman with CMV-R. Vitreous haemorrhage, 
retinal detachment and retinitis are shown by the retinal opacification with associated retinal 
haemorrhages indicative of active CMV-R. The picture appears out of focus because the vitreous 
haemorrhage is anterior to the retina.







both intravitreal ganciclovir and ART, but did 
not resolve in the participant who received 
ART only.  All 4 participants reported 
resolution of their systemic symptoms.
Visual acuity outcomes are presented in 
Table 2. Among the 5 participants who were 
followed up to month 6, there was no recorded 
deterioration in visual acuity from enrolment; 
6 eyes demonstrated no change and 4 eyes 
showed slight improvement.
Uveitis resolved in 2 of 3 cases, and 
in the third case where it persisted, a 
cataract developed. There were no cases of 
endophthalmitis.
Discussion
This study found a low incidence of CMV-R at a 
resource-constrained public hospital outpatient 
ophthalmology clinic in Ga-Rankuwa, South 
Africa: only 8 cases were identified in a 1-year 
period. The low incidence may be explained by 
the availability of ART in this population.
In this setting, CMV-R remains an AIDS 
manifestation, and the late presentation to 
care is highlighted not only by the low median 
CD4 count of 20 cells/μl but also by the 
advanced stage of visual loss at enrolment.
Several studies from the pre-ART era 
describe improved or stable visual outcomes 
with intravitreal ganciclovir injections for 
CMV-R lesions.12,13 Importantly, even though 
none of the 75% of participants who reported 
systemic symptoms received systemic 
ganciclovir, the combination of ART and 
intravitreal ganciclovir did ameliorate visual 
symptoms in our study. However, possibly 
owing to severe visual loss, no patient had 
complete recovery of vision. 
Currently the authors are unable to predict 
whether the 6-month outcomes reported here 
would have been better if state-of-the-art 
treatments such as ganciclovir implants and 
systemic valganciclovir had been available 
in our setting. A pressing question in the 
field of cytomegalovirus medicine is the 
relative efficacy of localised versus systemic 
treatment when CMV-R has been diagnosed, 
and until this is answered, management 
remains individualised. When comparing 
localised with systemic treatments, the latter 
carry an increased risk of systemic side-effects 
but also a reduced risk of systemic CMV 
dissemination.
There are several limitations to our study. 
First, the small sample size prevents statistical 
comparison of outcomes by treatment 
combination. Second, incidence may be 
underestimated because of missed diagnoses 
and lack of presentation to hospital. Third, 
when screening for systemic symptoms of 
CMV infection, no attempt was made to 
discriminate from co-morbidities. It has been 
noted, however, that systemic CMV symptoms 
have been misdiagnosed as Pneumocystis 
jirovecii pneumonia and tuberculosis, among 
others.14 Last, though we attempted in our 
mortality assessment to control for treatment 
defaulting by telephonic tracing, loss to 
follow-up may signify an underestimation of 
mortality, a phenomenon well described in 
studies of ART programmes.15
In conclusion, CMV-R is an uncommon 
disease in the ART era in Ga-Rankuwa, South 
Africa. Intravitreal ganciclovir, complemented 
with ART, was an effective option to treat 
CMV-R.
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Table 2. Visual acuity at enrolment and month 6
Right eye (N=8) Left eye (N=8)
Visual acuity category Enrolment Month 6 Enrolment Month 6
6/6 - 6/12 vision 0 0 4 2
6/18 - 6/60 vision 2 2 0 0
Counting fingers to hand motions vision 3 1 2 2
Light perception to no light perception 3 2 2 1
Defaulted/died Not applicable 3 Not applicable 3
